Invité venusien Posté(e) 25 mars 2006 Share Posté(e) 25 mars 2006 Vénusien, nous sommes bien d'accord, mais Primary outcome A total of 21 out of 29 patients (72%) in the TI group and 13 out of 29 (45%) in the lamivudine group had discontinued the study by week 48 (P Â¼ 0.061). Two patients discontinued for reasons other than immunological or clinical failure (one TI patient withdrew his consent, one lamivudine patient died in a working accident). Treatment failures were thus 20 of 29 patients (69%; 95% CI 51–83%) in the TI group (17 immunological failures, two clinical, and one both) and 12 of 29 patients (41%; 95% CI 26–59%) in the lamivudine group (11 immunological failures and one clinical; P Â¼ 0.064). Tous les patients en êchec (immunologique et/ou clinique) ont redémarré la tri. Citer Lien vers le commentaire Partager sur d’autres sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.